Clinical & Experimental Metastasis

, Volume 33, Issue 1, pp 87–95 | Cite as

Potent anti-tumor effects of EGFR-targeted hybrid peptide on mice bearing liver metastases

  • Arong Gaowa
  • Tomohisa Horibe
  • Masayuki Kohno
  • Hiroshi Harada
  • Masahiro Hiraoka
  • Koji Kawakami
Research Paper


In this study, we investigated the therapeutic efficacy of EGFR2R-lytic hybrid peptide for the treatment of liver metastasis from colon carcinoma. The cytotoxic activity of the hybrid peptide against luciferase-expressing human colon cancer (HCT-116-luc) cells was determined by the WST-8 assay. The experimental mouse model of liver metastases was generated by splenic injection of HCT-116-luc cells. The hybrid peptide was intravenously injected into mice the day after cell implantation at a dose of 5 mg/kg and this was repeated on alternate days for a total of 7 doses. Saline-treated mice were used as controls. Tumor growth and therapeutic responses were monitored by an IVIS imaging system. It was shown that the hybrid peptide exhibited potent cytotoxic activity against HCT-116-luc cells and the liver metastases were significantly reduced after intravenous injections of hybrid peptide compared with controls. Furthermore, Kaplan–Meier analysis showed that hybrid peptide-treated mice had significantly longer survival than controls. In addition, bright-field and ex vivo imaging of liver tissue revealed that mice treated with the hybrid peptide had significantly fewer tumors compared with controls. These results demonstrated that the EGFR2R-lytic hybrid peptide is a potential treatment option for patients with colorectal cancer metastases in the liver.


Liver metastases Colorectal cancer Hybrid peptide Epidermal growth factor receptor Anti-tumor effect 



Epidermal growth factor receptor


Vascular endothelial growth factor


Phosphate buffered saline




Hematoxylin and eosin


Aspartate transaminase


Alanine aminotransferase


Lactate dehydrogenase


Tyrosine kinase



We thank Mitsuko Tachi, Yoshie Masuda and Nanako Okushima (Department of Pharmacoepidemiology, Kyoto University) for their technical assistance in cell culture and animal studies. This study was supported by Grants-in-Aid for Young Scientist (A) (Grant No. 23680089) from the Japan Society for the Promotion of Science. This study was also supported in part by a collaboration research fund from Olympus Corporation.

Compliance with ethical standards

Conflict of interest

Koji Kawakami serves as a scientific advisor to Olympus Corporation. None of the other authors have any potential competing interest.

Supplementary material

10585_2015_9760_MOESM1_ESM.doc (41 kb)
Supplementary material 1 (DOC 41 kb)
10585_2015_9760_MOESM2_ESM.docx (17 kb)
Supplementary material 2 (DOCX 17 kb)


  1. 1.
    Hawk ET, Linburg PJ, Viner JL (2002) Epidemiology and prevention of colorectal cancer. Surg Clin N Am 82(5):905–941CrossRefPubMedGoogle Scholar
  2. 2.
    Patanaphan V, Salazar OM (1993) Colorectal cancer: metastatic patterns and prognosis. South Med J 86(1):38–41CrossRefPubMedGoogle Scholar
  3. 3.
    Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77(11):1241–1246CrossRefPubMedGoogle Scholar
  4. 4.
    Clark ME, Smith RR (2014) Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol 5(5):374–387PubMedCentralPubMedGoogle Scholar
  5. 5.
    Tol J, Punt CJ (2010) Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 32(3):437–453CrossRefPubMedGoogle Scholar
  6. 6.
    Reubi JC, Maecke HR (2008) Peptide-based probes for cancer imaging. J Nucl Med 49(11):1735–1738CrossRefPubMedGoogle Scholar
  7. 7.
    Thundimadathil J (2012) Cancer treatment using peptides: current therapies and future prospects. J. Amino Acids 2012:967347PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Kohno M, Horibe T, Haramoto M, Yano Y, Ohara K, Nakajima O, Matsuzaki K, Kawakami K (2011) A novel hybrid peptide targeting EGFR-expressing cancers. Eur J Cancer 47(5):773–783CrossRefPubMedGoogle Scholar
  9. 9.
    Tada N, Horibe T, Haramoto M, Ohara K, Kohno M, Kawakami K (2011) A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity. Biochem Biophys Res Commun 407(2):383–388CrossRefPubMedGoogle Scholar
  10. 10.
    Kawamoto M, Horibe T, Kohno M, Kawakami K (2011) A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer 11:359–372PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Yang L, Horibe T, Kohno M, Haramoto M, Ohara K, Puri RK, Kawakami K (2012) Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy. Mol Cancer Ther 11(1):235–243CrossRefPubMedGoogle Scholar
  12. 12.
    Horibe T, Kawamoto M, Kohno M, Kawakami K (2012) Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90. J Biosci Bioeng 114(1):96–103CrossRefPubMedGoogle Scholar
  13. 13.
    Gaowa A, Horibe T, Kohno M, Sato K, Harada H, Hiraoka M, Tabata Y, Kawakami K (2014) Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled release and enhancement of anti-tumor activity in vivo. J Control Release 176:1–7CrossRefPubMedGoogle Scholar
  14. 14.
    Amador ML, Hidalgo M (2004) Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer. Clin Colorectal Cancer 4(1):51–62CrossRefPubMedGoogle Scholar
  15. 15.
    Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, Beelen RH, van de Winkel JG, van Egmond M (2008) Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol 181(10):6829–6836CrossRefPubMedGoogle Scholar
  16. 16.
    Kohno M, Horibe T, Ohara K, Ito S, Kawakami K (2014) The membrane-lytic peptides K8L9 and melittin enter cancer cells via receptor endocytosis following subcytotoxic exposure. Chem Biol 21(11):1522–1532CrossRefPubMedGoogle Scholar
  17. 17.
    Haramoto M, Kohno M, Nakajima O, Horibe T, Kiyohara M, Fukazawa H, Togawa T, Kawakami K (2010) Pancreatic cancer therapy with a novel pump for controlled drug release. Oncol Rep 23(2):365–370PubMedGoogle Scholar
  18. 18.
    Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O, Majumdar AP (2005) Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 4(3):435–442PubMedGoogle Scholar
  19. 19.
    Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C (2006) In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 57(6):709–718CrossRefPubMedGoogle Scholar
  20. 20.
    Wu XZ, Ma F, Wang XL (2010) Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol 16(32):4084–4088PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Rajput A, Dominguez San Martin I, Rose R, Beko A, Levea C, Sharratt E, Mazurchuk R, Hoffman RM, Brattain MG, Wang J (2008) Characterization of HCT116 human colon cancer cells in an orthotopic model. J Surg Res 147(2):276–281CrossRefPubMedGoogle Scholar
  22. 22.
    Ishizu K, Sunose N, Yamazaki K, Tsuruo T, Sadahiro S, Makuuchi H, Yamori T (2007) Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol Pharm Bull 30(9):1779–1783CrossRefPubMedGoogle Scholar
  23. 23.
    Kyriazis AP, DiPersio L, Michael GJ, Pesce AJ, Stinnett JD (1978) Growth patterns and metastatic behavior of human tumors growing in athymic mice. Cancer Res 38(10):3186–3190PubMedGoogle Scholar
  24. 24.
    Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR (1984) Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 44(8):3522–3529PubMedGoogle Scholar
  25. 25.
    Giavazzi R, Jessup JM, Campbell DE, Walker SM, Fidler IJ (1986) Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst 77(6):1303–1308PubMedGoogle Scholar
  26. 26.
    Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N, Nakamura M (2007) Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice. Int J Oncol 31(4):741–751PubMedGoogle Scholar
  27. 27.
    Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50(19):6130–6138PubMedGoogle Scholar
  28. 28.
    Bouvet M, Tsuji K, Yang M, Jiang P, Moossa AR, Hoffman RM (2006) In vivo color-coded imaging of the interaction of colon cancer cells and splenocytes in the formation of liver metastases. Cancer Res 66(23):11293–11297CrossRefPubMedGoogle Scholar
  29. 29.
    Fu XY, Besterman JM, Monosov A, Hoffman RM (1991) Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 88(20):9345–9349PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Wang X, Fu X, Hoffman RM (1992) A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. Int J Cancer 51(6):992–995CrossRefPubMedGoogle Scholar
  31. 31.
    An Z, Jiang P, Wang X, Moossa AR, Hoffman RM (1999) Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection. Clin Exp Metastasis 17(3):265–270CrossRefPubMedGoogle Scholar
  32. 32.
    Humphries MJ, Olden K, Yamada KM (1986) A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233(4762):467–470CrossRefPubMedGoogle Scholar
  33. 33.
    Komazawa H, Saiki I, Igarashi Y, Azuma I (1993) Inhibition of tumor metastasis by a synthetic polymer containing a cell-adhesive RGDS peptide. J Bioact Compat Polym 8:258–274CrossRefGoogle Scholar
  34. 34.
    Schimanski CC, Linnemann U, Berger MR (1999) Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 59(20):5169–5175PubMedGoogle Scholar
  35. 35.
    Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757–1765CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • Arong Gaowa
    • 1
  • Tomohisa Horibe
    • 1
  • Masayuki Kohno
    • 1
  • Hiroshi Harada
    • 2
  • Masahiro Hiraoka
    • 2
  • Koji Kawakami
    • 1
  1. 1.Department of Pharmacoepidemiology, Graduate School of Medicine and Public HealthKyoto UniversityKyotoJapan
  2. 2.Department of Radiation Oncology and Image-applied Therapy, Graduate School of MedicineKyoto UniversityKyotoJapan

Personalised recommendations